The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology
█ Current opinion
Authors:
Joerg Herrmann1*, Teresa López-Fernández2, and Alexander R. Lyon3
1Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
2Division of Cardiology; Cardiac Imaging and Cardio-Oncology Unit; La Paz University Hospital, IdiPAZ Research Institute, Paseo de la Castellana 261, 28046 Madrid, Spain
3Cardio-Oncology Service, Royal Brompton Hospital, Guy’s and St. Thomas’ NHS Foundation Trust, Sydney Street, SW3 6NP, London, UK
*Corresponding author. Tel: 001-507-284-2904, Fax: 001-507-266-0228, Email: herrmann.joerg@mayo.edu, Twitter: @mayocvonc
The 2022 European Society Cardiology (ESC) guidelines on cardio-oncology include 272 recommendations and 48 figures, most of them algorithms, to provide much-needed direction in this field (1). Due to the lack of large-scale, randomized trials, only 3% of the recommendations were level of evidence (LOE) A (21% LOE B and 76% LOE C). The guidelines were composed by a large expert task force and critically reviewed by an equally esteemed panel of reviewers and are the first official guidelines in this area by a major cardiovascular (CV) society. The changing patient perspective with the trajectory of CV disease before, during, and after cancer diagnosis and treatment are key elements. The guidelines emphasize assessment of risk using Heart Failure Association (HFA)-International Cardio-Onco-logy Society (ICOS) risk assessment tools before initiation of therapy. Based on the stratification of risk, either low, intermediate, or high/very high, different courses of preventive and surveillance strategies are recommended to ensure that CV problems are managed appropriately to enable the most effective and least interfered upon cancer treatment.
ISSUE: CARDIOLOGIA HUNGARICA | 2023 | VOLUME 53, ISSUE 2
click here to read the full article |
click here to read the pdf |
||